Fractyl Health Stock Earnings Reports

Fractyl Health provided a business and financial update for Q1 2026 focused heavily on clinical progress for Revita (endoscopic duodenal ablation) and early clinical initiation for Rejuva (AAV-based, pancreatic-targeted GLP-1 gene therapy). Management reaffirmed four commitments: (1) the clinical signal for Revita is real and supported by dose-response and patient-selection data, (2) the REMAIN-1 pivotal trial (300+ randomized participants, >30 U.S. sites) is executing on plan with >90% retention and topline 6-month pivotal data expected in early Q4 2026, (3) commercial and reimbursement preparations are advancing (CPT Category III filing planned, transitional pass-through payment pathway, potential benefit from CMS RAPID pathway), and (4) the company has sufficient cash runway into early 2027 and does not plan a capital raise prior to receiving pivotal data. Near-term clinical catalysts include REVEAL-1 12-month open-label data (Q2), REMAIN-1 midpoint cohort 12-month randomized data (Q3), pivotal 6-month topline data (early Q4), and potential de novo submission in late Q4 2026. Rejuva (RJVA-001) received Netherlands authorization to start a Phase I/II 3x3 first-in-human study, with first dosing and preliminary data expected in H2 2026 (pending site activation); Australia regulatory feedback expected in Q3. Financially, R&D spend fell to $15.6M (Q1), SG&A was flat at $5.2M, adjusted EBITDA was negative $18M, and reported net income of $9.2M was driven by a $30.1M noncash warrant-liability fair value gain. Cash and equivalents were $63.2M as of March 31, 2026, which management says funds operations into early 2027 (beyond anticipated pivotal readout and potential de novo submission).